This is what analysts have to say about Celgene Corporation (NASDAQ:CELG) after last week.

Celgene Corporation (NASDAQ:CELG) Logo
Investors sentiment increased to 0.76 in 2019 Q1. Its up 0.12, from 0.64 in 2018Q4. It increased, as 108 investors sold Celgene Corporation shares while 441 reduced holdings. 204 funds opened positions while 213 raised stakes. 482.72 million shares or 1.75% less from 491.33 million shares in 2018Q4 were reported.
Brown Brothers Harriman has invested 0.01% in Celgene Corporation (NASDAQ:CELG). Two Sigma Secs Ltd Liability has invested 0% in Celgene Corporation (NASDAQ:CELG). Rhenman Prtn Asset Mgmt Ab reported 65,698 shares. First Foundation Advisors reported 3,090 shares. Fulton National Bank Na has 0.18% invested in Celgene Corporation (NASDAQ:CELG) for 27,381 shares. Community Bank Na, New York-based fund reported 3,922 shares. Swedbank reported 0.44% of its portfolio in Celgene Corporation (NASDAQ:CELG). Allstate Corp, Illinois-based fund reported 46,770 shares. Capital Invest Advsr owns 2,175 shares. Massachusetts-based Acadian Asset Mgmt Limited Liability Company has invested 0% in Celgene Corporation (NASDAQ:CELG). Moreover, Great West Life Assurance Co Can has 0.17% invested in Celgene Corporation (NASDAQ:CELG) for 671,314 shares. Armistice Capital Llc has 3.06% invested in Celgene Corporation (NASDAQ:CELG) for 592,000 shares. Art Advisors Limited Com invested in 0.5% or 88,560 shares. Fcg Advisors Limited Liability holds 5.69% or 182,302 shares in its portfolio. Montana-based Davidson Invest Advisors has invested 1.37% in Celgene Corporation (NASDAQ:CELG).

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Among 5 analysts covering Celgene (NASDAQ:CELG), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Celgene has $103 highest and $95 lowest target. $100.20’s average target is 7.38% above currents $93.31 stock price. Celgene had 16 analyst reports since February 26, 2019 according to SRatingsIntel. Cantor Fitzgerald maintained the stock with “Hold” rating in Monday, June 24 report. The firm has “Buy” rating by Jefferies given on Thursday, February 28. The firm has “Buy” rating given on Tuesday, March 12 by Robert W. Baird. As per Thursday, February 28, the company rating was maintained by Robert W. Baird. The firm has “Buy” rating given on Monday, June 24 by Mizuho. Cantor Fitzgerald maintained it with “Buy” rating and $100 target in Thursday, February 28 report. Below is a list of Celgene Corporation (NASDAQ:CELG) latest ratings and price target changes.

24/06/2019 Broker: Mizuho Rating: Buy New Target: $103 Maintain
24/06/2019 Broker: Cantor Fitzgerald Rating: Hold New Target: $100 Maintain
03/05/2019 Broker: BidaskScore Rating: Hold Upgrade
03/05/2019 Broker: Barclays Capital Old Rating: Overweight New Rating: Equal-Weight Downgrade
26/04/2019 Broker: BidaskScore Rating: Sell Downgrade
05/04/2019 Broker: Cantor Fitzgerald Old Rating: Overweight New Rating: Neutral Downgrade
01/04/2019 Broker: Bernstein Old Rating: Outperform New Rating: Market Perform Downgrade
01/04/2019 Broker: UBS Old Rating: Buy New Rating: Neutral Downgrade
01/04/2019 Broker: Atlantic Securities Old Rating: Overweight New Rating: Neutral Downgrade
26/03/2019 Broker: Canaccord Genuity Rating: Hold Maintain

The stock increased 0.45% or $0.42 during the last trading session, reaching $93.31. About 2.19 million shares traded. Celgene Corporation (NASDAQ:CELG) has risen 3.32% since August 15, 2018 and is uptrending. It has outperformed by 3.32% the S&P500.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. The company has market cap of $66.13 billion. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes , and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. It has a 12.75 P/E ratio. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Nasdaq.com which released: “Stock Market Today: Boeing, Tesla Tumble on More Worries – Nasdaq” on July 25, 2019, also Streetinsider.com with their article: “Baupost’s 13F Shows New Stake in XPO Logistics (XPO), Increase in Bristol-Myers Squibb (BMY), CBS (CBS), Liquidated Celgene (CELG) (More…) – StreetInsider.com” published on August 13, 2019, Nasdaq.com published: “Is a Beat in the Cards for Celgene’s (CELG) Q2 Earnings? – Nasdaq” on July 24, 2019. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Seekingalpha.com and their article: “Celgene: Timing The Switch To Bristol-Myers – Seeking Alpha” published on August 08, 2019 as well as Nasdaq.com‘s news article titled: “Bristol-Myers Squibb Stock Has Upside — But Mind the Risks – Nasdaq” with publication date: August 12, 2019.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.